Siplizumab
- Generic Name
- Siplizumab
- Drug Type
- Biotech
- CAS Number
- 288392-69-8
- Unique Ingredient Identifier
- KUW1QG1ZM3
- Indication
Investigated for use/treatment in psoriasis and psoriatic disorders, transplant (rejection), graft versus host disease, lymphoma (unspecified), and leukemia (unspecified).
Non-Myeloablative HLA-Mismatched Ex-Vivo T-cell Depleted Stem Cell Transplantation for Hematologic Malignancies
Phase 2
Terminated
- Conditions
- LymphomaMultiple MyelomaMyelodysplastic SyndromeLeukemia
- First Posted Date
- 2005-06-10
- Last Posted Date
- 2018-03-16
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 14
- Registration Number
- NCT00113646
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
Study to Evaluate MEDI-507 in Patients With CD2-Positive Lymphoma/Leukemia
Phase 1
Terminated
- Conditions
- LymphomaLeukemiaCancer
- First Posted Date
- 2005-03-14
- Last Posted Date
- 2007-06-14
- Lead Sponsor
- MedImmune LLC
- Target Recruit Count
- 80
- Registration Number
- NCT00105313
- Locations
- 🇺🇸
USC/Norris Cancer Center, Los Angeles, California, United States
🇺🇸Yale Cancer Center, New Haven, Connecticut, United States
🇺🇸Georgetown University Medical Center, Lombardi Comprehensive Cancer Center, Washington, District of Columbia, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath